Based on the Sanofi SA stock forecast from 0 analysts, the average analyst target price for Sanofi SA is not available over the next 12 months. Sanofi SA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sanofi SA is Bullish , which is based on 11 positive signals and 4 negative signals. At the last closing, Sanofi SA’s stock price was EUR 91.62. Sanofi SA’s stock price has changed by +7.50% over the past week, +2.20% over the past month and -12.43% over the last year.
No recent analyst target price found for Sanofi SA
No recent average analyst rating found for Sanofi SA
Company Overview Sanofi SA
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. Read Less
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides special...Read More
Frequently Asked Questions About Sanofi SA (SAN:PA) Stock
Stock Target Advisor's fundamental analysis for Sanofi SA's stock is Bullish .
SAN:PA stock's dividend yield is 4.13%.
Our analysis grades SAN:PA stock's dividend yield at A+. This means that SAN:PA stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - General sector in the PA exchange.
Based on this SAN:PA may be a good dividend stock for its sector.
Unfortunately we do not have enough data on SAN:PA's stock to indicate what its average analyst target is.
SAN:PA stock's Price/Earning ratio is 21.15.
Our analysis grades SAN:PA stock's Price / Earning ratio at A+. This means that SAN:PA stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - General sector in the PA exchange.
Based on this SAN:PA may be undervalued for its sector.
The last closing price of SAN:PA's stock was EUR 91.62.
The most recent market capitalization for SAN:PA is EUR 113.54B.
Unfortunately we do not have enough analyst data on SAN:PA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sanofi SA's stock.
As per our most recent records Sanofi SA has 86,088 Employees.
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SAN:PA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
